Skip to content

SPY Fluorescence Imaging Systems and Indocyanine Green to Determine the Percentage of Successful Critical Anatomy Recognition in Laparoscopic Cholecystectomy Surgeries.

SPY Fluorescence Imaging Systems and Indocyanine Green to Determine the Percentage of Successful Critical Anatomy Recognition in Laparoscopic Cholecystectomy Surgeries.

Status
Terminated
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05006950
Enrollment
50
Registered
2021-08-16
Start date
2021-06-28
Completion date
2022-09-07
Last updated
2022-09-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cholecystitis

Brief summary

This is a prospective single arm, single center study estimating percentage of successful critical anatomy recognition in laparoscopic cholecystectomy surgeries using SPY fluorescence imaging and ICG, with each surgery also providing a white light 360 degree images. The primary objective is to determine the percentage of successful critical anatomy recognition using intra-operative SPY fluorescence imaging and ICG: and to describe complications associated with intra-operative decision making in patients undergoing laparoscopic cholecystectomy.

Interventions

DEVICEStryker1688 Fluorescence imaging system

The purpose of this study is to use SPY fluorescence imaging systems and indocyanine green (ICG) as a tool to determine the percentage of successful critical anatomy recognition and to describe complications associated with intra-operative decision making in patients undergoing laparoscopic cholecystectomy.

Sponsors

Stryker Endoscopy
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Subject is 18 years of age or older * Subject is scheduled to undergo laparoscopic cholecystectomy, elective or emergent * Subject provides informed consent and signs an approved informed consent document for the study * Subject is willing to comply with the protocol and study visit schedule

Exclusion criteria

* Subject is pregnant or lactating * Subject has a known allergy or history of adverse reaction to ICG, iodine or iodine dyes * Subject has known history of cholangitis, pancreatitis, prior bile duct injury, coagulopathy or known pre-existing liver disease * Subjects who, in the Investigator's opinion, have any medical condition that may make the subject a poor candidate for the investigation, interferes with the interpretation of study results, or integrity of the study

Design outcomes

Primary

MeasureTime frameDescription
Outcome 1Intra-op visitTo determine the percentage of successful critical anatomy recognition using intra-operative SPY fluorescence imaging and ICG in subjects undergoing laparoscopic cholecystectomy

Secondary

MeasureTime frameDescription
Outcome 2Intra-op visitTo estimate the number of times a surgeon altered the surgical plan due to information identified/revealed by SPY fluorescence imaging

Other

MeasureTime frameDescription
Outcome 3Post op follow- up (7-14 days)To estimate the number of post-operative complications (related to gall bladder surgery

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026